A gaggle of heavyweights dominated the Bristol-Myers Squibb/Celgene/Amgen deal that helped close out the summer in M&A.  

Thousand Oaks, California, based multinational biopharmaceutical giant Amgen agreed last week to purchase psoriasis pill Otezla from Summit, New Jersey, biotech firm Celgene for $13.4 billion. Celgene’s divestiture of the product was mandated to avoid an antitrust obstacle that came up during Bristol-Myers Squibb’s announced acquisition of Celgene in January for $74 billion ($95 billion including debt) in what is one of the largest pharma acquisitions ever.